Potassium Channel Blockers and Openers as CNS Neurologic Therapeutic Agents
Recent Patents on CNS Drug Discovery · 01.11.2007 · 2 (3) · 200-228
DOI: 10.2174/157488907782411765 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Recent Patents on CNS Drug Discovery, erschienen am 01.11.2007. Verfasst von Susan I V Judge und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. sjudge@umaryland.edu. Die Arbeit wurde bisher 44-mal zitiert (Crossref).
Abstract (Originalsprache)
Potassium (K+) channels are the most heterogeneous and widely distributed class of ion channels. K(+) channels are dynamic pore-forming transmembrane proteins known to play important roles in all cell types underlying both normal and pathophysiological functions. Essential for such diverse physiological processes as nerve impulse propagation, muscle contraction, cellular activation and the secretion of biologically active molecules, various K(+) channels are recognized as potential therapeutic targets in the treatment of multiple sclerosis, Alzheimer's disease, Parkinson's disease, epilepsy, stroke, brain tumors, brain/spinal cord ischemia, pain and schizophrenia, migraine, as well as cardiac arrhythmias, pulmonary hypertension, diabetes, cervical cancer, urological diseases and sepsis. In addition to their importance as therapeutic targets, certain K(+) channels are gaining attention for their beneficial roles in anesthesia, neuroprotection and cardioprotection. The K(+) channel gene families (subdividing into multiple subfamilies) include voltage-gated (K(v): K(v)1-K(v)12 or KCNA-KCND, KCNF-KCNH, KCNQ, KCNS), calcium-activated (K(Ca): K(Ca)1-K(Ca)5 or KCNM-KCNN), inwardly rectifying (K(ir): K(ir)1-K(ir)7 or KCNJ) and background/leak or tandem 2-pore (K(2P): K(2P)1-K(2P)7, K(2P)9-K(2P)10, K(2P)12-K(2P)13, K(2P)15-K(2P)18 or KCNK) K(+) channels. Worldwide, the pharmaceutical industry is actively developing better strategies for targeting ion channels, in general, and K(+) channels, in particular, already generating over $6 billion in sales per annum from drugs designed to block or modulate ion channel function. This review provides an overview of recent patents on emerging K(+) channel blockers and activators (openers) with potential for development as new and improved nervous system therapeutic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. sjudge@umaryland.edu
Zitieren
APA
Judge, S. I., Smith, P. J., Stewart, P. E., & Bever, C. T. (2007). Potassium Channel Blockers and Openers as CNS Neurologic Therapeutic Agents. Recent Patents on CNS Drug Discovery, 2(3), 200-228. https://doi.org/10.2174/157488907782411765
Vancouver
Judge SI, Smith PJ, Stewart PE, Bever CT. Potassium Channel Blockers and Openers as CNS Neurologic Therapeutic Agents. Recent Patents on CNS Drug Discovery. 2007;2(3):200-228. doi:10.2174/157488907782411765
BibTeX
@article{Judge2007,
author = {Judge, Susan I V and Smith, Paul J and Stewart, Peggy E and Bever, Christopher T},
title = {Potassium Channel Blockers and Openers as CNS Neurologic Therapeutic Agents},
journal = {Recent Patents on CNS Drug Discovery},
year = {2007},
volume = {2},
number = {3},
pages = {200--228},
doi = {10.2174/157488907782411765}
}
EUVIMED